We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enable... Monte Rosa Therapeutics Inc is a biopharmaceutical company involved in developing a portfolio of novel small molecule precision medicines that employ the body's natural mechanisms to degrade therapeutically relevant proteins. It has developed a protein degradation platform, called QuEEN, that enables to rapidly identify protein targets and molecular glue degrader, or MGD, product candidates. Show more
BOSTON, July 08, 2024 (GLOBE NEWSWIRE) -- Monte Rosa Therapeutics, Inc. (Nasdaq: GLUE), a clinical-stage biotechnology company developing novel molecular glue degrader (MGD)-based medicines...
Ongoing Phase 1/2 Study of MRT-2359 for MYC-driven solid tumors demonstrates favorable safety and pharmacodynamic profile dosing 0.5 mg using a 21/7 schedule; currently assessing 0.75 mg dose...
MRT-6160, a VAV1-directed molecular glue degrader (MGD), inhibits disease progression, pro-inflammatory cytokines and autoantibody production in a model of rheumatoid arthritis Initiation of...
Period | Change | Change % | Open | High | Low | Avg. Daily Vol | VWAP | |
---|---|---|---|---|---|---|---|---|
1 | 0.13 | 3.28282828283 | 3.96 | 4.36 | 3.54 | 259046 | 3.72494854 | CS |
4 | 0.12 | 3.02267002519 | 3.97 | 4.49 | 3.32 | 265878 | 3.74147496 | CS |
12 | -2.33 | -36.292834891 | 6.42 | 6.46 | 3.32 | 221848 | 4.43154248 | CS |
26 | -2.12 | -34.1384863124 | 6.21 | 8.84 | 3.32 | 178829 | 5.23482793 | CS |
52 | -2.6 | -38.8639760837 | 6.69 | 8.84 | 2.44 | 205482 | 4.94625868 | CS |
156 | -16.43 | -80.0682261209 | 20.52 | 45.56 | 2.44 | 203926 | 10.41426856 | CS |
260 | -17.91 | -81.4090909091 | 22 | 45.56 | 2.44 | 209347 | 10.81841916 | CS |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions